Avastin and Herceptin sales fuel Genentech income rise

Share this article:
Genentech reported a third-quarter net income that rose 56 percent aided by sales of its colon cancer drug Avastin (bevacizumab) and breast cancer drug Herceptin (trastuzumab).
 Avastin sales rose 78 percent to $325.2 million. Sales of breast cancer drug Herceptin rose 70 percent to $215 million.
Although sales of Avastin leveled off for its FDA-approved indication, colon cancer, doctors are starting to use it off-label for breast and lung cancer. Off-label prescribing has also boosted sales of Herceptin. The drug is approved for the treatment of metastatic breast cancer in certain women, however doctors are trying it in earlier stages of the disease.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union